June S&P 500 futures (ESM23) are up +0.09%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.12% this morning as market participants continued to monitor U.S. debt-ceiling negotiations while awaiting...
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA...
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company...
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities...
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross...
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering...
Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned...
IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and...
IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice...
Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company...